NCT04677530View on ClinicalTrials.gov

A Study of JNJ-40411813 in Healthy Japanese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

May 21, 2021

Study Completion Date

May 21, 2021

Conditions
Healthy
Interventions
DRUG

JNJ-40411813

JNJ-40411813 will be administered orally.

DRUG

Matching Placebo

Matching placebo will be administered orally.

Trial Locations (1)

813-0017

Souseikai Fukuoka Mirai Hospital, Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY